| Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19 J Hammond, H Leister-Tebbe, A Gardner, P Abreu, W Bao, ... New England Journal of Medicine 386 (15), 1397-1408, 2022 | 1718 | 2022 |
| Augmentin ® (amoxicillin/clavulanate) in the treatment of community-acquired respiratory tract infection: a review of the continuing development of an … AR White, C Kaye, J Poupard, R Pypstra, G Woodnutt, B Wynne Journal of Antimicrobial Chemotherapy 53 (suppl_1), i3-i20, 2004 | 280 | 2004 |
| Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria GJ Noel, RS Strauss, K Amsler, M Heep, R Pypstra, JS Solomkin Antimicrobial agents and chemotherapy 52 (1), 37-44, 2008 | 202 | 2008 |
| Probability of target attainment for ceftobiprole as derived from a population pharmacokinetic analysis of 150 subjects TP Lodise Jr, R Pypstra, JB Kahn, BP Murthy, HC Kimko, K Bush, GJ Noel, ... Antimicrobial agents and chemotherapy 51 (7), 2378-2387, 2007 | 89 | 2007 |
| Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community … H Lode, TM File Jr, L Mandell, P Ball, R Pypstra, M Thomas, ... Clinical therapeutics 24 (11), 1915-1936, 2002 | 87 | 2002 |
| Oral gemifloxacin once daily for 5 days compared with sequential therapy with iv ceftriaxone/oral cefuroxime (maximum of 10 days) in the treatment of hospitalized patients with … R Wilson, C Langan, P Ball, K Bateman, R Pypstra, ... Respiratory medicine 97 (3), 242-249, 2003 | 52 | 2003 |
| Population pharmacokinetics of recombinant human C1 inhibitor in patients with hereditary angioedema C Farrell, S Hayes, A Relan, ES van Amersfoort, R Pijpstra, CE Hack British journal of clinical pharmacology 76 (6), 897-907, 2013 | 41 | 2013 |
| Investigators EH. Oral nirmatrelvir for high-risk, nonhospitalized adults with COVID-19 J Hammond, H Leister-Tebbe, A Gardner, P Abreu, W Bao, ... N Engl J Med 386 (15), 1397-408, 2022 | 33 | 2022 |
| Immunosafety of recombinant human C1-inhibitor in hereditary angioedema: evaluation of IgE antibodies CE Hack, A Relan, A Baboeram, B Oortwijn, S Versteeg, R van Ree, ... Clinical drug investigation 33, 275-281, 2013 | 16 | 2013 |
| Summary of the safety and tolerability of two treatment regimens of ceftaroline fosamil: 600 mg every 8 h versus 600 mg every 12 h K Cheng, R Pypstra, JL Yan, J Hammond Journal of Antimicrobial Chemotherapy 74 (4), 1086-1091, 2019 | 13 | 2019 |
| Treatment of complicated skin and skin structure infections caused by Gram-positive bacteria with ceftobiprole: results of a double-blind, randomized trial GJ Noel, RS Strauss, K Amsler, M Heep, R Pypstra, JS Solomkin Antimicrob Agents Chemother 52 (1), 37-44, 2008 | 11 | 2008 |
| Immuno-Safety of Recombinant Human C1 Inhibitor in Patients With Hereditary Angioedema: An Integrated Analysis E Hack, A Relan, L Kaufman World Allergy Organization S 45, 2012 | 7 | 2012 |
| Gemifloxacin 207 Clinical Study G. Oral gemifloxacin once daily for 5 days compared with sequential therapy with iv ceftriaxone/oral cefuroxime (maximum of 10 days) in the … R Wilson, C Langan, P Bali, K Bateman, R Pypstra Respir Med 97 (3), 242-9, 2003 | 7 | 2003 |
| In-vitro activity of diverse β-lactam/aai101 combinations vs. Multidrug-resistant gram-negative clinical strains S Mushtaq, A Chaudhry, R Adkin, N Woodford, N Benedict, R Pypstra, ... Proceedings of the ECCMID, 2014 | 6 | 2014 |
| Dose justification for recombinant human C1INH for the treatment of acute angioedema attacks in patients with hereditary angioedema A Relan, G Haase, E Hack, J Nuijens, B Giannetti, R Pijpstra Allergy 65, 445-446, 2010 | 6 | 2010 |
| 185 Gemifloxacin Study Group: Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients … H Lode, TM File Jr, L Mandell, P Ball, R Pypstra, M Thomas Clin Ther 24, 1915-1936, 2002 | 6 | 2002 |
| Pharmacokinetics (PK) of multiple infusions of ceftobiprole (1000 mg every 8 hours) in healthy volunteers [abstract no. A-1943] A Schmitt-Hoffmann, B Murthy, RS Strauss, R Pypstra 46th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy …, 2006 | 5 | 2006 |
| Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits J Hammond, H Leister-Tebbe, A Gardner, P Abreu, W Bao, ... Open Forum Infectious Diseases 9 (2), ofac492. 047, 2022 | 4 | 2022 |
| Clinical value of the treatment with rhC1INH of patients with hereditary angioedema suffering from an acute peripheral angioedema attack R Pijpstra, A Relan, G Haase, A Kusuma, M Cicardi, E Hack, B Giannetti, ... Allergy 65, 444-445, 2010 | 4 | 2010 |
| 1156. Sustained alleviation and resolution of targeted COVID-19 symptoms with nirmatrelvir/ritonavir versus placebo J Hammond, H Leister-Tebbe, A Gardner, P Abreu, W Bao, ... Open Forum Infectious Diseases 9 (Supplement_2), ofac492. 994, 2022 | 3 | 2022 |
